Skip to main content
Clinical Trials/NCT05087095
NCT05087095
Completed
Not Applicable

Managing Distress in Malignant Brain Cancer

Virginia Commonwealth University1 site in 1 country13 target enrollmentMarch 23, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer Metastatic to Brain
Sponsor
Virginia Commonwealth University
Enrollment
13
Locations
1
Primary Endpoint
Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains
Status
Completed
Last Updated
last year

Overview

Brief Summary

To identify potential adaptations of the managing cancer and living meaningfully (CALM) intervention that will be required for service members, Veterans, their beneficiaries, and civilian cancer metastasis to the brain (bMET) populations.

Detailed Description

Single-arm, mixed-methods, Phase IIa, proof-of-concept trial to inform CALM adaptations for service members (SMs), Veterans, their beneficiaries, and civilians with bMET.

Registry
clinicaltrials.gov
Start Date
March 23, 2022
End Date
November 1, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of brain metastasis (bMET) confirmed via medical records, radiography or histopathology
  • At least 2 weeks post-surgical cranial resection or cranial biopsy (if applicable)
  • Score \> 20 on the TICS
  • Report elevated depression (PHQ-9 score ≥ 10) OR death anxiety symptoms (DADDS score ≥ 15)
  • Ability to read, speak, and understand English
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Major communication difficulties, which would prohibit psychotherapeutic interaction
  • Inability to meet with interventionist via an electronic device for telehealth intervention sessions
  • Inability to understand and provide informed consent
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk

Outcomes

Primary Outcomes

Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains

Time Frame: 4 Months

At the exit interview, participants will be asked to rate the applicability of the four CALM domains on a Likert Scale from 1 (not applicable) to 5 (very applicable). The four CALM domains are as follows: Domain 1) represents symptom management and communication with healthcare providers, Domain 2) reflects changes in personal relationships, Domain 3) sense of meaning and purpose, and Domain 4) the future, hope and mortality. Higher scores mean greater applicability.

Feasibility of CALM Intervention in the Proof of Concept Project as Measured by Attendance at CALM Sessions

Time Frame: 3 Months

Percent of sessions attended across all participants

Feasibility of CALM Intervention in the Proof of Concept Project as Measured by the Rates of Participant Screening, Eligibility, and Consent.

Time Frame: 12 months

Determine how many patients consent to screening after referral to the program, how many patients are eligible for the program after being screened, and how many consent/enroll in the program if eligible.

Feasibility of CALM Intervention in the Proof of Concept Project as Measured by the Rates of Post-session Assessment Completion

Time Frame: 3 Months

Percent of post-session surveys completed by participants immediately after the intervention

Feasibility of CALM Intervention in the Proof of Concept Project as Measured by Post-intervention Assessment Completion

Time Frame: 3 Months

Percent of post-intervention surveys completed

Benefit of Intervention in the Proof of Concept Project

Time Frame: 4 Months

Benefit will be assessed by participant responses to a question during the exit interview (e.g., Rate your overall benefit on a scale of 1-5).

Study Sites (1)

Loading locations...

Similar Trials